Method and kit for detecting biomarker related to myocardial hypertrophy disease

Abstract

The invention discloses a method for detecting a biomarker related to the myocardial hypertrophy disease in the technical field of biology. The method comprises the steps of: S1: establishing myocardial hypertrophy related candidate miRNA, i.e., screening out key miRNA influencing formation of myocardial hypertrophy from literatures, designing a primer for the candidate key miRNA by adopting a polyA tail method, and carrying out subsequent identification on the designed primer; S2: screening a to-be-selected target microRNA small sample, i.e., carrying out a quantitative detection reaction ofmicroRNA on the small sample by using a kit, preparing Real Time PCR reaction solution on ice by using a fluorescent quantitative instrument, and then carrying out a quantitative PCR reaction; and S3:verifying a to-be-selected target microRNA large sample. According to the method, the myocardial hypertrophy related microRNA identification method is high in efficiency; and the method adopts a plurality of pieces of microRNA to carry out myocardial hypertrophy identification and screening and is more accurate.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a detection method and kit for biomarkers related to cardiac hypertrophy disease. Background technique [0002] Myocardial hypertrophy is a heart disease affected by many factors, and it is recognized as one of the important causes of sudden myocardial death and heart failure. Since Jarcho et al. first reported that the missense mutation of cardiac myosin heavy chain gene MYH6 can lead to cardiac hypertrophy, a large number of studies have successively discovered 13 pathogenic genes and more than 900 mutation sites related to cardiac hypertrophy. Genetic evidence suggests that dominant mutations encoding myofilament proteins that control sarcomere contraction can induce cardiac hypertrophy. Up to now, 70% of patients with cardiac hypertrophy carry mutations in MYH7 or muscle protein binding protein MYBPC3; about 5% of patients with cardiac hypertrophy carry mutations in troponin TNN...

AI Technical Summary

Problems solved by technology

[0006] The regulatory mechanism of cardiac hypertrophy at the transcriptional level and epigenetic level still lacks sufficient molecular biological and clinical evidence; in addition, compared with the wide application of genomics and molecular biology in the field of tumors, the research and clinical The conversion is relatively lagging behind

Images